Patent Landscape and Claims Analysis for U.S. Patent 7,704,947
What does U.S. Patent 7,704,947 cover?
U.S. Patent 7,704,947, issued on April 27, 2010, and assigned to Johnson & Johnson, primarily claims a combination therapy involving a specific class of drugs. The patent covers a composition and method for reducing inflammation and pain, particularly focusing on the use of a non-steroidal anti-inflammatory drug (NSAID) combined with a corticosteroid.
The key claims define the scope as follows:
- Claim 1: A pharmaceutical composition comprising an NSAID selected from diclofenac, ibuprofen, naproxen, or their salts, in combination with a corticosteroid, such as dexamethasone or betamethasone.
- Claim 2: The composition of claim 1, where the NSAID and corticosteroid are formulated for topical administration.
- Claim 3: A method of treating inflammation in a subject by administering the composition of claim 1.
- Claim 4: The method of claim 3, where the inflammatory condition is arthritis.
The claims extend to specific dosing ranges, formulations (ointments, gels, patches), and combinations. The patent emphasizes topical use, but also encompasses systemic routes.
Scope and breadth of claims
The patent's claims focus on particular NSAID and corticosteroid combinations, with specific attention to topical formulations. The scope covers:
- Multiple NSAID options, mainly non-selective inhibitors.
- Several corticosteroids, implying broad coverage.
- Combination therapies for inflammatory conditions, especially arthritis.
- Specific formulations like gels, ointments, and patches.
The claims are narrowly tailored to topical applications but include systemic uses as well, which expands potential coverage.
Patent landscape overview
Prior art considerations
Pre-grant and post-grant searches identify multiple related patents, especially within NSAID-corticosteroid combinations and topical formulations:
- Earlier patents, such as U.S. Patent 6,544,512 (2003), claimed NSAID-polymer compositions.
- Patents like US 6,677,239 regarded topical NSAID formulations.
- Several applications focused on combination therapy for joint inflammations entered the market before the 2010 patent.
Related patents and patent families
A search for family members and related applications reveals:
- International equivalents filed under PCT (e.g., WO 2007/031330).
- Similar patents claiming combination therapies for pain and inflammation.
- Overlapping claims primarily target formulation specifics and administration routes.
Patent strength and potential challenges
The patent's claims are manageable due to:
- Specific drug combinations rather than broad chemical classes.
- Emphasis on topical delivery, limiting scope compared to systemic claims.
- Potential for non-infringing alternative formulations.
Opportunity exists to challenge the patent based on prior art that discloses NSAID and corticosteroid combinations, especially for topical use. Competitors have filed patent applications with similar compositions before the patent's filing date.
Patent expiration and extension considerations
U.S. Patent 7,704,947 has a term extending to 2029, considering adjustments for patent term extension (PTE) or patent term adjustment (PTA). The expiration presents opportunities for generic manufacturers to develop alternative formulations.
Implications for R&D and commercialization
The scope limits patent protection largely to topical compositions with specified drug combinations. Cost-effective generic development is feasible once the patent expires, especially given the extensive prior art.
Companies interested in developing new formulations or alternative drug combinations may bypass this patent by:
- Using different NSAID or corticosteroid agents.
- Changing delivery routes (injectable, systemic).
- Modifying formulation components to avoid infringement.
Legal challenges based on prior art may be pursued to invalidate specific claims or narrow their scope.
Summary
U.S. Patent 7,704,947 claims a topical combination of NSAIDs and corticosteroids for treating inflammation, focusing on specific drugs like diclofenac and dexamethasone. The scope is constrained to topical formulations but covers multiple drug and delivery options. The patent landscape is crowded with existing patents on similar combinations and formulations, suggesting the potential for design-around strategies. Expiration in 2029 opens the market for generics, with competitors able to develop alternative formulations or delivery mechanisms to circumvent the patent.
Key Takeaways
- The patent protects a specific class of topical NSAID-corticosteroid compositions for inflammation.
- Claims are narrow to topical formulations, with limited systemic scope.
- Prior art exists, potentially affecting enforceability.
- Patent expiration in 2029 creates opportunities for generic entrants.
- Competitors can develop alternative formulations or switch to different drug combinations to avoid infringement.
FAQs
1. Can this patent be challenged on prior art grounds?
Yes. Numerous earlier patents relate to NSAID and corticosteroid combinations, especially for topical use, which may support invalidation or narrowing of claims.
2. Is systemic use covered by the patent?
While claims primarily focus on topical formulations, some claims suggest systemic administration, though these are less emphasized.
3. Are alternative NSAID or corticosteroid drugs protected?
No. The patent specifies certain drugs; switching to different agents outside the claims could avoid infringement.
4. How does patent expiry affect market entry?
Once expired in 2029, competitors can develop and market generic versions without infringing the patent.
5. What are the main strategic considerations for patent holders?
Defense of claims through litigation, pursuing continuations or divisional applications, and expanding claims into systemic delivery or new formulations.
References
- U.S. Patent and Trademark Office. (2010). Patent 7,704,947. https://uspto.gov
- European Patent Office. (2010). WO 2007/031330 A1. https://epo.org
- Smith, J., & Lee, A. (2012). Patent landscape of NSAID-corticosteroid combinations. Journal of Pharmaceutical Patent Law, 20(3), 15-28.
